Hormonal
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.
GLP-1 RAs like semaglutide and tirzepatide are highly effective medications for weight loss, producing 15-22% body weight loss in clinical trials. They work by mimicking gut hormones to reduce appetite and improve metabolic health. They are not a 'magic bullet' but a tool that works best when combined with dietary changes, physical activity, and psychological support. Common side effects like nausea are usually temporary and manageable. These drugs are particularly useful for those who have struggled with long-term weight maintenance through lifestyle changes alone.
The STEP-1 RCT demonstrated the efficacy and safety of Semaglutide 2.4 mg... with a mean weight loss of 15%... The subsequent SURMOUNT RCT demonstrated that the dual GLP-1/GIP... RA, Tirzepatide, showed greater efficacy with participants losing 22.5% at 72 weeks... the SELECT trial... showed participants using Semaglutide 2.4 mg had a 20% reduction in major adverse cardiovascular events
Why this rating
Based on multiple large-scale RCTs (STEP-1, SURMOUNT, SELECT) cited in the text.
Source
“From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of <scp>GLP</scp>‐1 receptor agonists in obesity management services
Adrian Brown et al. · Nutrition Bulletin · 2024
DOI 10.1111/nbu.12700
More from this paper
- GLP-1 RA treatment is associated with significant lean tissue (muscle) loss, with studies showing 14-40% of total weight loss being lean mass, necessitating interventions to preserve muscle.Good
- Discontinuation of GLP-1 RA therapy is associated with significant weight regain, suggesting that these medications may need to be used as long-term maintenance treatments rather than short-term interventions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →